Preference values associated with stage III colon cancer and adjuvant chemotherapy

Quality of Life Research

Volumn 19, Issue 3, 2010, Pages 391-400

  Best, Jennie H ^a   Garrison, Louis P ^a   Hollingworth, William ^a   Ramsey, Scott D ^a   Veenstra, David L ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Chemotherapy; Colon cancer; Preferences; Time trade off; Utilities

Indexed keywords

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER STAGING; COLORECTAL TUMOR; COST BENEFIT ANALYSIS; FEMALE; HOSPITALIZATION; HUMAN; MALE; MIDDLE AGED; PATHOLOGY; PATIENT ATTITUDE; PSYCHOLOGICAL ASPECT; QUALITY ADJUSTED LIFE YEAR; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PATIENT PREFERENCE; QUALITY-ADJUSTED LIFE YEARS; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS;

EID: 77952554374     PISSN: 09629343     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11136-010-9589-5     Document Type: Article

References (38)

1. Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., & Thun, M. J. (2007). Cancer statistics, 2007. CA: A Cancer Journal for Clinicians, 57, 43-66.
2. National Comprehensive Cancer Network. (2005). Clinical practice guideline in oncology-Colon cancer (v.2.2006).
3. Ramsey, S. D. (2007). How should we pay the piper when he's calling the tune? On the long-term affordability of cancer care in the United States. Journal of Clinical Oncology, 25, 175-179.
4. Schrag, D. (2004). The price tag on progress-Chemotherapy for colorectal cancer. NEJM, 351(4), 317-319.
5. Twelves, C., Wong, A., Nowacki, M. P., Abt, M., Burris, H., 3rd, Carrato, A., et al. (2005). Capecitabine as adjuvant treatment for stage III colon cancer. NEJM, 352(26), 2696-2704.
6. André, T., Boni, C., Mounedji-Boudiaf, L., Navarro, M., Tabernero, J., Hickish, T., et al. (2004). Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. NEJM, 350(23), 2343-2351.
7. Gold, M. R., Siegel, J. E., Russel, L. B., & Weinstein, M. C. (Eds.). (1996). Cost-effectiveness in health and medicine. New York: Oxford University Press.
8. National Institute for Clinical Excellence. (2004). Guide to the methods of technology appraisal.
9. National Institute for Clinical Excellence. (2005). Social value judgements. Guidelines for the institute and its advisory bodies.
10. Brown, M. L., Nayfield, S. G., & Shibley, L. M. (1994). Adjuvant therapy for stage III colon cancer: Economic returns to research and cost-effectiveness of treatment. Journal of the National Cancer Institute, 86(6), 424-430.
11. Kievit, J., & van de Velde, C. J. (1990). Utility and cost of carcinoembryonic antigen monitoring in colon cancer follow-up evaluation. A Marhov analysis. Cancer, 65(11), 2580-2587.
12. Smith, R. D., Hall, J., & Gurney, H. (1993). A cost-utility approach to the use of 5-fluorouracil and levamisole as adjuvant chemotherapy for Dukes' C colonic carcinoma. Medical Journal of Australia, 158(5), 319-322.
13. Dominitz, J. A., & Provenzale, D. (1997). Patient preferences and quality of life associated with colorectal cancer screening. The American Journal of Gastroenterology, 92(12), 2171-2178.
14. Boyd, N. F., Sutherland, H. J., Heasman, K. Z., Tritchler, D. L., & Cummings, B. J. (1990). Whose utilities for decision analysis? Medical Decision Making, 10(1), 58-67.
15. Norum, J., Vonen, B., Olsen, J. A., & Revhaug, A. (1997). Adjuvant chemotherapy (5-fluorouracil and levamisole) in Dukes' B and C colorectal carcinoma. A cost-effectiveness analysis. Annals of Oncology, 8(1), 65-70.
16. Ness, R. M., Holmes, A. M., Klein, R., & Dittus, R. (1999). Utility valuations for outcome states of colorectal cancer. American Journal of Gastroenterology, 94(6), 1650-1657.
17. Ramsey, S., Andersen, M. R., Etzioni, R., Moinpour, C., Peacock, S., Potosky, A., et al. (2000). Quality of life in survivors of colorectal carcinoma. Cancer, 88(6), 1294-1303.
18. Ramsey, S. D., Berry, K., & Etzioni, R. (2002). Lifetime cancerattributable cost of care for long-term survivors of colorectal cancer. American Journal of Gastroenterology, 97(2), 440-445.
19. Lloyd, A., De Jonge, P., Doyle, S., Walker, M., & Cohen, C. (2006). Developing health state descriptions for metastatic colorectal cancer: A qualitative study. Value in Health, 9(3), A115.
20. Shaw, J. W., Johnson, J. A., & Coons, S. J. (2005). US valuation of the EQ-5D health states: Development and testing of the D1 model. Medical Care, 43(3), 203-220.
21. Salomon, J., & Murray, C. J. L. (2004). A multi-method approach to measuring health-state valuations. Health Economics, 13, 281-290.
22. Torrance, G. W. (1987). Utility approach to measuring healthrelated quality of life. Journal of Chronic Diseases, 40(6), 593-600.
23. Furlong, W., Feeny, D., & Torrance, G. W., et al. (1990). Guide to design and development of health-state utility instrumentation. McMaster University Working paper 90-99.
24. Stalmeier, P. F., Goldstein, M. K., Holmes, A. M., Lenert, L., Miyamoto, J., Stiggelbout, A. M., et al. (2001). What should be reported in a methods section on utility assessment? Medical Decision Making, 21, 200-207.
25. Lenert, L. A., Cher, D. J., Goldstein, M. K., Bergen, M. R., & Garber, A. (1998). The effect of search procedures on utility elicitations. Medical Decision Making, 18(1), 76-83.
26. Elkin, E. B., Cowen, M. E., Cahill, D., Steffel, M., & Kattan, M. W. (2004). Preference assessment method affects decision-analytic recommendations: A prostate cancer treatment example. Medical Decision Making, 24, 504-510.
27. Torrance, G. W., Feeny, D., & Furlong, W. (2001). Visual analog scales: Do they have a role in the measurement of preferences for health states? Medical Decision Making, 21, 329-334.
28. Dolan, P., & Kahneman, D. (2008). Interpretations of utility and their implications for the valuation of health. The Econmic Journal, 118, 215-234.
29. Smith, M. D., Drummond, M., & Brixner, D. (2009). A different approach to health state valuation. Value in Health, 12(S1), S16-S17.
30. Grothey, A. (2005). Clinical management of oxaliplatin-associated neurotoxicity. Clinical Colorectal Cancer, 5(Suppl 1), S38-S46.
31. Stiggelbout, A. M., & de Haes, J. C. (2001). Patient preference for cancer therapy: An overview of measurement approaches. Journal of Clinical Oncology, 19(1), 220-230.
32. Van Osch, S. V., Wakker, P. P., Van Den Hout, W. B., & Stiggelbout, A. M. (2004). Correcting biases in standard gamble and time tradeoff utilities. Medical Decision Making, 24, 511-517.
33. Martin, A. J., Glasziou, P. P., Simes, R. J., & Lumley, T. (2000). A comparison of standard gamble, time trade-off, and adjusted time trade-off scores. International Journal of Technology Assessment in Health Car, 16(1), 137-147.
34. Read, J. L., Quinn, R. J., Berwick, D. M., Fineberg, H. V., & Weinstein, M. C. (1984). Preferences for health outcomes: Comparison of assessment methods. Medical Decision Making, 4, 315-329.
35. Jansen, S. J. T., Kievit, J., Nooij, M., & Stiggelbout, A. M. (2001). Stability of patients' preferences for chemotherapy: The impact of experience. Medical Decision Making, 21(4), 295-306.
36. Gabriel, S. E., Kneeland, T. S., Melton, L. J., Moncur, M. M., Ettinger, B., & Tosteson, A. N. (1999). Health-related quality of life in economic evaluations for osteoporosis: Whose values should we use? Medical Decision Making, 19(2), 141-148.
37. Patrick, D. L., Starks, H. E., Cain, K. C., Uhlmann, R. F., & Pearlman, R. A. (1994). Measuring preferences for health states worse than death. Medical Decision Making, 14, 9-18.
38. Robinson, A., & Spencer, A. (2006). Exploring challenges to TTO utilities: Valuing states worse than dead. Health Economics, 15, 393-402.